Liver Tumor Program, Temple University Hospital, Philadelphia, PA, USA.
J Multidiscip Healthc. 2013 May 9;6:189-95. doi: 10.2147/JMDH.S41206. Print 2013.
A multidisciplinary model is a useful approach in the management of hepatocellular carcinoma (HCC) to coordinate, individualize, and optimize care. The HCC Multidisciplinary Team (MDT) at Temple University Hospital was established in 2008 and comprises hepatologists, interventional radiologists, transplant surgeons, oncologists, residents, midlevel providers, and support staff. Patients may be enrolled by referral from (1) oncologists at Temple, (2) the hepatitis screening clinic recently established at Temple and staffed by hepatology residents, or (3) community practices. MDT conferences are held weekly, during which cases are discussed (based on medical history, interpretation of images, and laboratory analyses) and treatment plans are formulated. The Temple treatment algorithm follows current standards of care, guided by tumor volume and morphology, but the novel multidisciplinary interaction challenges members to tailor therapy to achieve the best possible outcomes. Patients with a solitary lesion ≤ 2 cm may receive no treatment until eligible for transplantation or locoregional therapy or resection, with imaging every 3 to 6 months to monitor tumor progression. In patients with tumors > 2 cm and ≤ 5 cm, microwave ablation therapy is used if lesions are discrete and accessible. Conventional transarterial chemoembolization (TACE) or drug-eluting bead TACE (DEB-TACE) or yttrium-90 microspheres are utilized in multifocal disease. Patients with lesions > 5 cm are candidates for TACE for downstaging the tumor. Sorafenib is typically reserved for unresectable lesions between 2 cm and 5 cm. Frequently, we administer sorafenib continuously and in combination with DEB-TACE. In our experience, sorafenib does not produce effects on the tumor vasculature or blood flow that would impair the efficacy of DEB-TACE. The literature documents improved outcomes in HCC and other cancers associated with the introduction of multidisciplinary care. The role and organization of the MDT is influenced by team culture, expertise, and process, as well as institutional and larger environmental contexts.
多学科模式是肝细胞癌(HCC)管理的一种有效方法,可协调、个体化和优化治疗。天普大学医院的 HCC 多学科团队(MDT)成立于 2008 年,由肝脏病学家、介入放射学家、移植外科医生、肿瘤学家、住院医师、中级医务人员和支持人员组成。患者可通过以下途径转介加入:(1)天普的肿瘤学家,(2)最近在天普开设的肝炎筛查诊所,由肝脏病学住院医师负责,或(3)社区诊所。MDT 会议每周举行一次,在此期间讨论病例(根据病史、图像解读和实验室分析)并制定治疗计划。天普的治疗算法遵循当前的护理标准,以肿瘤体积和形态为指导,但新颖的多学科互动挑战成员,使他们能够定制治疗以实现最佳结果。直径≤2cm 的单发病变患者可能在符合移植或局部区域治疗或切除条件之前无需治疗,每隔 3 至 6 个月进行影像学检查以监测肿瘤进展。肿瘤直径>2cm 且≤5cm 的患者,若病变孤立且可接近,则采用微波消融治疗。多发病灶采用常规经动脉化疗栓塞(TACE)或载药微球 TACE(DEB-TACE)或钇-90 微球治疗。肿瘤直径>5cm 的患者适合 TACE 降期肿瘤。索拉非尼通常保留用于直径 2cm 至 5cm 的不可切除病变。我们经常连续给予索拉非尼,并与 DEB-TACE 联合使用。根据我们的经验,索拉非尼对肿瘤血管或血流没有产生影响,不会削弱 DEB-TACE 的疗效。文献记录表明,引入多学科护理可改善 HCC 和其他癌症的预后。MDT 的作用和组织受团队文化、专业知识和流程以及机构和更大的环境背景影响。